DoctoRx Unscripted

Епізоди

• 
  Lung Cancer – No Longer the Disease We Once Thought It Was 20.05.2026 44хв

  Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a forward-looking episode of DoctoRx Unscripted, featuring leading thoracic oncologists Dr. Christine Lovly and Dr. Nate Pennell.Together, they examine innovations redefining what’s possible for patients with lung cancer: Biomarker-driven therapy and molecular profiling; Liquid biopsy and ctDNA testing; AI-assisted detection and radiomics; and Next-generation immunotherapies, including bispecifics, T-cell engagers, and personalized vaccines. They also share their perspectives on a critical challenge: translating scientific progress into real-world impact by expanding access and closing gaps in care.If you're working to advance oncology care—or interested in deepening your understanding of what’s shaping its future—this is a conversation you don’t want to miss.
• 
  Part 3 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight 25.02.2026 38хв

  Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 3, Dr. Small sits down with patient advocate Lisa Salberg, founder of the Hypertrophic Cardiomyopathy Association (HCMA), to explore how a personal diagnosis evolved into a global movement—helping to establish more than 60 Centers of Excellence around the world. The conversation reinforces why embedding the patient voice early is essential to advancing cardiovascular medicine.
• 
  Part 2 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight 25.02.2026 53хв

  Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 2, Dr. Small welcomes HCM expert Dr. Matthew Martinez and leading cardiologist Dr. Nani Bhalla. Together, they examine why hypertrophic cardiomyopathy has historically been so difficult to detect—and what has changed in recent years to begin altering that trajectory. The discussion explores how earlier recognition, paired with more precise and individualized treatment decisions, can change outcomes in meaningful and lasting ways.
• 
  Part 1 - Hypertrophic Cardiomyopathy: Hidden in Plain Sight 25.02.2026 26хв

  Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. In Part 1, NFL tight end Tommy Sweeney shares his experience of being diagnosed with HCM. He reflects on his personal journey— from diagnosis and treatment decision making to his return to the NFL with his condition appropriately treated and well managed. His story underscores a sobering reality: HCM can remain undetected even in individuals who receive frequent medical screenings, like elite athletes.
• 
  Part 2 - Myeloma: The New Playbook 03.12.2025 35хв

  The Future of Myeloma Care: In the concluding conversation, Dr. Small and her guests look beyond today’s therapies to the innovations shaping tomorrow. From early detection and prevention to next-generation platforms and therapies, the discussion traces how biology, technology, and compassion are converging to change lives. They challenge outdated dogmas, champion smarter, safer treatment strategies, and remind us who this fight is truly for: the patients, families, and next generation of clinicians carrying the mission forward.
• 
  Part 1 - Myeloma: The New Playbook 03.12.2025 53хв

  The Bleeding Edge of Discovery: What does the next decade of myeloma care look like? In this first installment, Dr. Tania Small brings together three of the world’s foremost experts to explore the breakthroughs redefining hope in multiple myeloma. From minimal residual disease (MRD) as a new regulatory endpoint to the research of immune-based therapies and the transformative potential these may hold, the panel dissects how science is accelerating toward the possibility of a functional cure. They also tackle some of the field’s toughest questions: how to sequence therapy in an era of quads, bispecifics, and antibody-drug conjugates, and how to close the survival gap for underrepresented populations by translating biology into equitable access.
• 
  Colorectal Cancer: The Hidden Drivers 16.10.2025 57хв

  Dr. Tania Small sits down with Dr. Heinz-Josef Lenz, one of the world’s greatest minds in gastrointestinal medical research, for a thought-provoking conversation on the future of colorectal cancer (CRC) care. Together, they unpack the rising incidence of early-onset CRC and the factors driving the surge of new cases in younger patients. This conversation dives into cutting-edge innovations that are reshaping detection and treatment: • ctDNA liquid biopsies and minimal residual disease testing - revolutionizing how relapse is detected. • Next-generation diagnostics and precision screening, including AI-assisted colonoscopies - enabling earlier, more accurate identification. • Methylation profiling, tumor microenvironment and epigenetic therapies - advancing personalized therapy and novel treatments. • Immunotherapies and targeted agents - moving to the “front line” with the potential to transform treatment approaches into organ-preserving strategies. But the conversation doesn’t stop at science. Together, they examine the influence of lifestyle, disparities in access, and patient-driven data on survival. If you’re driving change in oncology, this episode offers practical insights on integrating molecular testing, rethinking prevention, and preparing for the innovations ahead.
• 
  Cancer. Detected. Disrupted. Defied: 2025 ASCO® Annual Meeting 06.08.2025 54хв

  In this special edition of DoctoRx Unscripted, Dr. Tania Small sits down with three of the most visionary leaders in oncology, Dr. Lillian Siu, Dr. Fabrice André and Dr. Howard “Skip” Burris for a provocative conversation on data that has the potential to redefine the future of cancer care. They unpack cutting-edge findings—from next-generation diagnostics and novel modalities to AI-powered trials, precision medicine, prevention and what’s coming next in oncology innovation. Dr. Siu, Dr. André and Dr. Burris are paid consultants for BMS.
• 
  Part 2: Alzheimer’s beyond memory: Dr. Grossberg on psychosis & prevention 20.06.2025 32хв

  Join Dr. Tania Small, in a compelling 2-part episode featuring Dr. George Grossberg, a world-renowned geriatric psychiatrist who’s been at the forefront of Alzheimer’s disease research and innovation for over 40 years. In part 2, they delve into groundbreaking science - from researching novel therapeutic targets and addressing Alzheimer’s psychosis to the power of patient-driven science in research and prevention.
• 
  Part 1: Alzheimer’s on the edge: Dr. Grossberg on a new paradigm of care 20.06.2025 27хв

  Join Dr. Tania Small, in a compelling 2-part episode featuring Dr. George Grossberg, a world-renowned geriatric psychiatrist who’s been at the forefront of Alzheimer’s disease research and innovation for over 40 years. In part 1, they uncover the subtle early signs of Alzheimer’s, the biomarker revolution, and tackle the challenges of health equity in Alzheimer’s care.
• 
  Unlocking Minds, Rewriting Futures: Dr. Ilan Melnick on Forensic Psychiatry & True Rehabilitation 22.05.2025 30хв

  What happens when someone in the grip of a psychotic break commits a crime? In this episode of DoctoRx Unscripted, host Dr. Tania Small sits down with renowned forensic psychiatrist Dr. Ilan Melnick to confront that dilemma head-on.
• 
  Rewiring reality: Dr. John Kane on the future of schizophrenia care 22.05.2025 26хв

  In the premiere episode of DoctoRx Unscripted — Dr. Tania Small sits down with globally respected psychiatrist, Dr. John Kane, to unpack the science, challenge entrenched assumptions, and reimagine what schizophrenia care can be. It’s a forward-looking conversation that equips you with fresh insights — and a new lens on what’s possible in psychiatry.